Compare Invesco Ltd. (IVZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Travere Therapeutics Inc. Common Stock — how do they compare? Invesco Ltd. trades at $27.87 (market cap $12.33B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Invesco Ltd. is far larger — about 2.5× Travere Therapeutics Inc. Common Stock's market cap, and Invesco Ltd. pays a 3.08% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IVZ | TVTX | |
|---|---|---|
Market Cap | $12.33B | $5.02B |
Volume | 4,127,288 | 2,060,842 |
Sector | Financials | Health |
52-Week High | $33.31 | $67.52 |
52-Week Low | $22.44 | $26.79 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $22.50B | $5.15B |
Dividend Yield | 3.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $28.92, down 1.16% today, with bearish technical signals dominating despite recent earnings beats. The company shows mixed fundamentals with negative net income margins but positive cash flow trends, while analyst consensus leans toward Hold with a $33.17 price target. Recent news highlights ETF expansion and AUM growth to $2.56 trillion in August 2026.
The outlook remains cautious due to profitability challenges and technical weakness, though valuation multiples appear reasonable and dividend payments provide income support. Key risks include earnings volatility and market-sensitive AUM, while institutional sentiment suggests limited near-term upside potential from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
